ENDPOINTS

Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids

Agios' blood disease treatment Pyrukynd passed a Phase 3 study in PK deficiency in children who do not regularly receive blood transfusions. The readout arrives after Pyrukynd last year failed to meet ...

Feb 13, 2025 - 17:12
 0
Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids
Agios' blood disease treatment Pyrukynd passed a Phase 3 study in PK deficiency in children who do not regularly receive blood transfusions. The readout arrives after Pyrukynd last year failed to meet ...
Read More

Tags:

Previous Article

Nature Conservancy Announces 17 New Solar Energy Projects In Appalachia

Next Article

Butchered skulls point to Europe’s Ice Age cannibals

Related Posts

States sue Trump administration over billions in NIH indirect cost cuts

States sue Trump administration over billions in NIH in...

Feb 10, 2025  0

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Novartis returns for its anticoagulant in up to $3.1B b...

Feb 11, 2025  0

What will pharma's share buyback shopping spree mean for M&A?

What will pharma's share buyback shopping spree mean fo...

Feb 11, 2025  0